PERTH, Australia – As the Delta variant of SARS-CoV-2 sweeps across the globe, drugs like Roche Holding AG’s interleukin-6 receptor inhibitor Actemra (tocilizumab) are being used, often off-label, to treat serious cases of COVID-19. That usage, however, is resulting in serious drug shortages that may leave some without treatment options.
PERTH, Australia – Imugene Ltd. has closed an AU$90 million (US$64 million) placement and an AU$5 million share repurchase plan that will allow the company to progress its CAR T pipeline through 2025 and pursue a collaboration with Celgene Corp. spin-off Celularity Inc.
Suzhou Abogen Biosciences Co. Ltd.’s $700 million series C fundraising provides tailwinds for the development of its messenger ribonucleic acid (mRNA) platform. The company plans to accelerate its COVID-19 mRNA vaccine clinical trial, develop other vaccine candidates and oncology programs.
Adlai Nortye Biopharma Co. Ltd.’s $100 million series D financing in July threw new light on the enticing prospect of targeting EP4 in prostaglandin (PGE2)-driven cancers, and a number of players are lined up in the space.
An update from China’s NMPA clarifying registration requirements and classification methods for drug-device combination products has been welcomed by industry as the regulator seeks to keep pace with fast-moving developments in the sector.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Amerimmune, Astrazeneca, Biophytis, Coherus, Exevir, Histogen, Innocare, Innovent, Junshi, Kyowa Kirin, Mei, Nrx, Senhwa, Telix, Tiziana Life Sciences, Transcenta, Zhaoke Ophthalmology.
RSS
